ARCHIVES

Taxol Recommended For Second Line Therapy In Platinum-Resistant Metastatic Ovarian Cancer

This article is from The Cancer Letter archive.

Vol. 18 No. 45 | November 20, 1992

Download PDF Visit The Full Archive

Related Articles

BSA Approves Provocative Questions RFA; NCI Announces Review of SAIC-Frederick, for caBIG Restructuring

June 24, 2011

FDA Approves Afinitor-Aromasin Regimen For Advanced HER2-Negative Breast Cancer

July 27, 2012

Waksal Pleads Guilty To Securities Fraud

October 18, 2002

New Grants In Ovarian Cancer Ok’d In Concepts By DCBDC Advisors

March 27, 1992

Novartis Submits Gleevec Data To FDA Seeking Approval For Use In GI Tumors.

October 26, 2001

FOCR Report Offers Recommendations, Definitions for CER

May 22, 2009